Hemochromatosis primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
Line 41: Line 41:
|>1.9
|>1.9
|}
|}
====Screening and diagnosis of hemochromatosis.WT, wild type; HII, histologic iron index; CII, chemical iron index; HH, hereditary hemochromatosis<ref name="pmid22675794">{{cite journal| author=Bacon BR| title=Hemochromatosis: discovery of the HFE gene. | journal=Mo Med | year= 2012 | volume= 109 | issue= 2 | pages= 133-6 | pmid=22675794 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22675794  }}</ref><ref name="pmid20492323">{{cite journal| author=Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma| title=Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. | journal=J Gastroenterol Hepatol | year= 2010 | volume= 25 | issue= 4 | pages= 657-63 | pmid=20492323 | doi=10.1111/j.1440-1746.2009.06167.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20492323  }}</ref><ref name="pmid25976957">{{cite journal| author=Adams PC| title=Epidemiology and diagnostic testing for hemochromatosis and iron overload. | journal=Int J Lab Hematol | year= 2015 | volume= 37 Suppl 1 | issue=  | pages= 25-30 | pmid=25976957 | doi=10.1111/ijlh.12347 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25976957  }}</ref><ref name="pmid25454304">{{cite journal| author=Salgia RJ, Brown K| title=Diagnosis and management of hereditary hemochromatosis. | journal=Clin Liver Dis | year= 2015 | volume= 19 | issue= 1 | pages= 187-98 | pmid=25454304 | doi=10.1016/j.cld.2014.09.011 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25454304  }}</ref><ref name="pmid23418762">{{cite journal| author=Crownover BK, Covey CJ| title=Hereditary hemochromatosis. | journal=Am Fam Physician | year= 2013 | volume= 87 | issue= 3 | pages= 183-90 | pmid=23418762 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23418762  }}</ref><ref name="pmid25864215">{{cite journal| author=Adams PC, Barton JC, Guo H, Alter D, Speechley M| title=Serum ferritin is a biomarker for liver mortality in the Hemochromatosis and Iron Overload Screening Study. | journal=Ann Hepatol | year= 2015 | volume= 14 | issue= 3 | pages= 348-53 | pmid=25864215 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25864215  }}</ref><ref name="pmid23862168">{{cite journal| author=Adams PC, McLaren CE, Speechley M, McLaren GD, Barton JC, Eckfeldt JH| title=HFE mutations in Caucasian participants of the Hemochromatosis and Iron Overload Screening study with serum ferritin level <1000 µg/L. | journal=Can J Gastroenterol | year= 2013 | volume= 27 | issue= 7 | pages= 390-2 | pmid=23862168 | doi= | pmc=3956024 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23862168  }}</ref><ref name="pmid25314357">{{cite journal| author=Lim A, Speechley M, Adams PC| title=Predicting C282Y homozygote genotype for hemochromatosis using serum ferritin and transferrin saturation values from 44,809 participants of the HEIRS study. | journal=Can J Gastroenterol Hepatol | year= 2014 | volume= 28 | issue= 9 | pages= 502-4 | pmid=25314357 | doi= | pmc=4205907 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25314357  }}</ref>====
 
{{familytree/start|summary=Algorithm for screening and diagnosis of hemochromatosis.WT, wild type; HII, histologic iron index; CII, chemical iron index; HH, hereditary hemochromatosis.}}
{{familytree| | | | | | | | | | | | |A01| | | | | | | | | |A01=Serum Transferin Saturation<br>TS}}
{{familytree| | | | | | | | | |,|-|-|-|^|-|-|-|.| | | | | | |}}
{{familytree| | | | | | | | | |!| | | | | | | |!| | | | | |}}
{{familytree| | | | | | | | |B01| | | | | |B02| | | | |B01=<50% premenupasal females<br><60% men, postmenupasal women|B02=≥50% premenupasal females<br>≥60% men, postmenupasal women}}
{{familytree| | | | | | | | | |!| | | | | | | |!| | | | |}}
{{familytree| | | | | | | | | |!| | | | | | |Q01| | | | |Q01=1 Repeat Transferin Saturation TS<br>2 Serum Feretin SF}}
{{familytree| | | | | | | | | |!| | |,|-|-|-|-|^|-|-|.| |}}
{{familytree| | | | | | | | |C01| |!| | | | | | | |!| | |C01=Repeat testing every 5 year}}
{{familytree| | | | | | | | |,|-|-|-|'| | | | | | | |!| | |}}
{{familytree| | | | | | | | |!| | | | | | | | | | | |!| |}}
{{familytree| | | | | | | | |D01| | | | | | | | |D02| |D01=TS:<50% premenupasal females<br>TS: <60% men, postmenupasal women<br>SF: 20-250μg/L premenupasal females<br>SF: 10-120μg/L men, postmenupasal women|D02=TS:≥50% premenupasal females<br>TS: ≥60% men, postmenupasal women<br>SF:>200 μg/L premenupasal females<br>SF:>300 μg/L men, postmenupasal women}}
{{familytree| | | | | | | | | |!| | | | | | |,|-|-|-|^|-|-|-|-|.|}}
{{familytree| | | | | | | | |E01| | | | |E02| | | | | | |E03|E01=Repeat TS and SF every 2-3 year|E02=Serum Feretin<1000 μg/L|E03=Serum Feretin>1000 μg/L}}
{{familytree| | | | | | | | | | | | | | | | |!|,|-|-|-|-|-|-|^|-|-|.|}}
{{familytree| | | | | | | | | | | | | | | |F01| | | | | | | | |F02|F01=Geno-typing|F02=Liver biopsy}}
{{familytree| | | | | | | | |,|-|-|v|-|-|-|^|-|-|v|-|-|.| | | | |,|-|^|-|.| |}}
{{familytree| | | | | | | |G01| |G02| | | |G03| |G04| | |G05| |G06|G01=WT/WT genotype|G02=C282Y/WT genotype|G03=C282Y/H63D genotype|G04=C282Y/C282Y genotype|G05=Histological iron index<0.15<br>Chemical iron index<2.0|G06=Histological iron index>0.15<br>Chemical iron index>2.0}}
{{familytree| | | | | | | | |`|-|V|-|'| | | | | |`|-|V|-|'| | | | |!| | |!|}}
{{familytree| | | | | | | | | |H01| | | | | | | |H02| | | | |H03| |H04|H01=Secondray hemochromatosis|H02=Phelebotomy to maintain Serum Feretin|H03=Repeat TS and SF after 2-3 year|H04=Phelebotomy to maintain Serum Feretin}}
{{familytree| | | | | | | | | | |!| | | | | | | | | |!| | |}}
{{familytree| | | | | | | | | |K01| | | | | | | |K02|K01=Screen family with Transferin Saturation & Serum Feretin if atypical HH suspected|K02=Screen family with genotyping}}
{{familytree| | | | | | | | | | | | | | | | | | | | |!| |}}
{{familytree| | | | | | | | | | | | | | | | | | | |J01|J01=Moniter Transferin Saturation & Serum Feretin in subclinical members}}
{{familytree/end}}
==References==
==References==
{{reflist|2}}
{{reflist|2}}

Latest revision as of 18:35, 1 January 2019

Hemochromatosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemochromatosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemochromatosis primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemochromatosis primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemochromatosis primary prevention

CDC on Hemochromatosis primary prevention

Hemochromatosis primary prevention in the news

Blogs on Hemochromatosis primary prevention

Directions to Hospitals Treating Hemochromatosis

Risk calculators and risk factors for Hemochromatosis primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sunny Kumar MD [2]

Overview

There is no primary prevention of inherited hemochormatosis. However conditions causing secondary iron load can be avoided. Screening family members of a person diagnosed with hemochromatosis may detect the disease early so that treatment can be started before organ damage has occurred in other affected relatives.

Primary Prevention

There is no primary prevention of inherited hemochormatosis. However conditions causing secondary iron load can be avoided. Screening family members of a person diagnosed with hemochromatosis may detect the disease early so that treatment can be started before organ damage has occurred in other affected relatives.

Measurements Asymptomatic Symptomatic
Serum iron level (μg/dL) 150-280 180-300
Serum transferrin saturation 45-100 80-100
Serum ferritin level (μg/L) Men 150-1000 500-6000
Female 120-1000 500-6000
Hepatic iron concentration μg/g dry weight 2000-10,000 8000-30,000
Perls' Prussian blue stain 2+ to 4+ 3+, 4+
Hepatic iron index >1.9 >1.9

References

Template:WS Template:WH